After announcing two major deals in December, GlaxoSmithKline CEO Emma Walmsley is optimistic about her efforts to transform Britain’s largest drugmaker.
div > div.group > p:first-child”>
Walmsley took the helm of GSK in April 2017. Since then, she has been pushing the pharma giant into the spotlight after it spent years hiding in the background. In December alone, the company announced the $5.1 billion acquisition of cancer drug specialist Tesaro and a joint venture with Pfizer that involves splitting up GSK’s two major businesses.
The joint venture, which will focus on consumer health care, will make it the No. 1 or No. 2 player in 10 of the world’s 15 biggest markets, Walmsley said. The extra cash flow will benefit GSK’s other business, pharmaceuticals and vaccines, she said.
“We need to place some smart bets, take some risks, and I think when we do that we’ll be bringing sustainable shareholder growth and more benefits for more patients around the world,” she said.
Investors seem to be buying into Walmsley’s strategy. Shares of the British company, which has a market value of $96.6 billion, finished 2018 up 7 percent.